Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.

× No keyword cloud information.

40 in total

1. LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective.

Authors: S Adebahr; S Collette; E Shash; M Lambrecht; C Le Pechoux; C Faivre-Finn; D De Ruysscher; H Peulen; J Belderbos; R Dziadziuszko; C Fink; M Guckenberger; C Hurkmans; U Nestle
Journal: Br J Radiol Date: 2015-04-15 Impact factor: 3.039

2. SEOM clinical guidelines for the treatment of non-small-cell lung cancer: an updated edition.

Authors: José Manuel Trigo Pérez; Pilar Garrido López; Enriqueta Felip Font; Dolores Isla Casado
Journal: Clin Transl Oncol Date: 2010-11 Impact factor: 3.405

Review 3. Pemetrexed: a review of its use in the management of advanced non-squamous non-small cell lung cancer.

Authors: Claudine M Baldwin; Caroline M Perry
Journal: Drugs Date: 2009-11-12 Impact factor: 9.546

4. Expression of peroxisome proliferator activated receptor-gamma (PPAR-γ) in human non-small cell lung carcinoma: correlation with clinicopathological parameters, proliferation and apoptosis related molecules and patients' survival.

Authors: Costantinos Giaginis; Ekaterini Politi; Paraskevi Alexandrou; John Sfiniadakis; Gregory Kouraklis; Stamatios Theocharis
Journal: Pathol Oncol Res Date: 2012-03-18 Impact factor: 3.201

5. Pattern of Imaging after Lung Cancer Resection. 1992-2005.

Authors: Gulshan Sharma; Shawn P E Nishi; Yu-Li Lin; Yong-Fang Kuo; James S Goodwin; Taylor S Riall
Journal: Ann Am Thorac Soc Date: 2016-09

6. Hu-antigen receptor (HuR) and cyclooxygenase-2 (COX-2) expression in human non-small-cell lung carcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients' survival.

Authors: Constantinos Giaginis; Paraskevi Alexandrou; Nikolaos Tsoukalas; Ioannis Sfiniadakis; Nikolaos Kavantzas; Emmanuel Agapitos; Efstratios Patsouris; Stamatios Theocharis
Journal: Tumour Biol Date: 2014-09-25

Review 7. Adjuvant or neoadjuvant chemotherapy for NSCLC.

Authors: Philip McElnay; Eric Lim
Journal: J Thorac Dis Date: 2014-05 Impact factor: 2.895

8. Erlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancer.

Authors: Katherine A Lyseng-Williamson
Journal: Pharmacoeconomics Date: 2010 Impact factor: 4.981

9. Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer.

Authors: Luis G Paz-Ares; Sedat Altug; Alexandra Thareau Vaury; Jesús Corral Jaime; Francesca Russo; Carla Visseren-Grul
Journal: BMC Cancer Date: 2010-03-08 Impact factor: 4.430

Review 10. Re-examination of maintenance therapy in non-small cell lung cancer with the advent of new anti-cancer agents.

Authors: Eamon M Berge; Robert C Doebele
Journal: Drugs Date: 2013-05 Impact factor: 9.546